Metokred is a combination of hypoglycemic agents, which includes glimepiride and metformin.


Metokred 501: Each film coated tablet contains:
Glimepride USP 1 mg
Metformin Hydrochloride USP 500 mg
Excipients q.s.
Approved colours used in coating
Metokred 502: Each film coated tablet contains:
Glimepride USP 2 mg
Metformin Hydrochloride USP 500 mg
Excipients q.s.
Approved colours used in coating

Indications for use

Treating type 2 diabetes (in addition to diet, exercise and weight loss):

  • When glycemic control cannot be achieved by a combination of diet, exercise, weight loss and monotherapy with glimepiride or metformin;
  • When replacing combination therapy with glimepiride and metformin with one combination drug.

Mode of administration

Typically, the dose Metokred must be determined target concentration of glucose in the patient’s blood. The lowest dose should be used, sufficient to achieve the desired metabolic control.
During treatment with Metokred must be regularly determine the concentration of glucose in the blood and urine. In addition, regular monitoring of the percentage of glycosylated hemoglobin in the blood is recommended.
An inappropriate drug intake, such as a missed dose, should never be replenished with a subsequent higher dose.
The patient’s actions in case of errors when taking the drug (in particular when skipping the next dose or skipping a meal), or in situations where it is not possible to take the drug, should be discussed by the patient and the doctor in advance.
Since the improvement of metabolic control associated with increased insulin sensitivity, in the course of treatment Metokred may decrease the need for glimepiride. In order to avoid the development of hypoglycemia should be promptly to reduce the dose or stop taking the medication Metokred.
The drug should be taken 1 or 2 times a day with meals.
The maximum dose of metformin per dose is 1000 mg.
Maximum daily dose: for glimepiride – 8 mg, for metformin – 2000 mg.
Only in a small number of patients is a daily dose of glimepiride more than 6 mg more effective.
In order to avoid hypoglycemia, the initial dose of the drug Metokred should not exceed daily doses glimepiride and metformin, which already takes patient. When transferring patients receiving a combination of separate preparations glimepiride and metformin on drug Metokred the dose determined on the basis of already received doses of glimepiride and metformin in separate formulations.
Duration of treatment. Usually, treatment with Metokred is carried out for a long time.